Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jordan Johnson

Physician Assistant Tulsa, OK Physician Assistant

NPI 1962040162 CMS profile 11187814

11912 S Norwood Ave Ste 110, Tulsa, OK 74137

Open in the dashboard

General payments

$5,592

252 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jordan Johnson of Tulsa, OK is reported in the CMS Open Payments database as having received $5,592 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,101 49
2024 General $1,519 72
2023 General $1,601 63
2022 General $779 42
2021 General $592 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordan Johnson
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jordan Johnson were reported at $1,101. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jordan Johnson Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $592 $132 $37–$438 $132
2022 $779 $155 $48–$522 $149
2023 $1,601 $167 $52–$557 $160
2024 $1,519 $178 $55–$600 $164
2025 $1,101 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $711 28 payments
  2. Philips Electronics North America Corporation $666 37 payments
  3. Merck Sharp & Dohme Corporation $560 27 payments
  4. Cordis US Corp. $532 27 payments
  5. Janssen Pharmaceuticals, Inc $368 14 payments
  6. Abbott Laboratories $330 14 payments
  7. Biotronik Inc. $319 12 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $290 16 payments
  9. Novartis Pharmaceuticals Corporation $231 11 payments
  10. Amgen Inc. $184 9 payments
  11. Other $1,401 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,367 246 payments
  2. Education $225 6 payments
Products named General payments · program years 2021–2025
  1. VERQUVO $797 38 payments
  2. XARELTO $368 14 payments
  3. General - Therapies $360 12 payments
  4. BioMonitor $303 11 payments
  5. LifeVest $290 16 payments
  6. Rivacor $225 6 payments
  7. Solia $225 6 payments
  8. Edora $225 6 payments
  9. Acticor $225 6 payments
  10. Repatha $184 9 payments
  11. Other $3,573 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,603

Median for Physician Assistant: 241

Drug cost

$388,671

Median for Physician Assistant: $4,110

Branded share of claims

28.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 149 $149,077
Entresto Sacubitril/Valsartan Brand 77 $83,560
Eliquis Apixaban Brand 53 $64,596
Brilinta Ticagrelor Brand 40 $29,351
Jardiance Empagliflozin Brand 20 $20,054
Vascepa Icosapent Ethyl Brand 16 $8,245
Valsartan Generic 173 $3,820
Varenicline Tartrate Generic 12 $3,634
Nebivolol Hcl Generic 58 $3,588
Metoprolol Succinate Generic 273 $3,388

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $237
$237 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $112
$112 77 —
Repatha
  • Amgen Inc. $105
$105 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $43
$43 20 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record